Summary
Alnylam Pharmaceuticals, Inc. (ALNY) announced on April 8, 2016, the completion of a significant land acquisition in Norton, Massachusetts, on April 4, 2016. The company purchased approximately 12 acres of undeveloped land for $8.0 million in cash, with the intention of developing a manufacturing facility on this site. This facility is planned to produce drug substance, including siRNAs and siRNA conjugates, which are critical for both clinical trials and eventual commercial supply. This strategic move signals Alnylam's commitment to vertically integrating its manufacturing capabilities and securing a robust supply chain for its innovative RNA interference (RNAi) therapeutics as it advances its pipeline.
Key Highlights
- 1Alnylam Pharmaceuticals acquired 12 acres of undeveloped land in Norton, Massachusetts.
- 2The transaction was completed on April 4, 2016.
- 3The purchase price for the land was approximately $8.0 million in cash.
- 4Alnylam plans to construct a dedicated manufacturing facility on the acquired land.
- 5The facility will be used for the production of drug substance, including siRNAs and siRNA conjugates.
- 6This investment supports Alnylam's strategy to enhance its manufacturing capabilities for its RNAi therapeutics.
- 7The facility is intended for both clinical and commercial supply needs.
Frequently Asked Questions
The primary purpose of the land acquisition was to establish a site for Alnylam Pharmaceuticals to construct a new manufacturing facility. This facility will be dedicated to producing drug substance, including siRNAs and siRNA conjugates, essential for the company's RNAi therapeutics pipeline.
Alnylam Pharmaceuticals paid approximately $8.0 million in cash for the land. The transaction was completed on April 4, 2016.
The new manufacturing facility is planned to produce drug substance, specifically including siRNAs and siRNA conjugates. These are key components for Alnylam's RNA interference (RNAi) therapeutics.
This acquisition is strategically important as it allows Alnylam to build its own manufacturing capabilities. This can lead to better control over its supply chain, ensure quality, potentially reduce costs, and support the advancement of its drug candidates from clinical development to commercialization.